AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2768606 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week interpersonal transaction (IT) group
Number of subjects: 65
Study 2768606 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week process group
Number of subjects: 65
Study 2768606 — intervention group
Group type: COMPARATOR
Intervention: Wait list condition
Number of subjects: 65
Study 172561 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalin‐inactivated decavalent rhinovirus vaccine 1
Number of subjects: 0
Study 172561 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalin‐inactivated decavalent rhinovirus vaccine 2
Number of subjects: 0
Study 172561 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29672740 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadadustat 300 mg once daily (QD)
Number of subjects: 94
Study 29672740 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadadustat 450 mg once daily (QD)
Number of subjects: 94
Study 29672740 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadadustat 450 mg thrice weekly (TIW)
Number of subjects: 94
Study 29672740 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all dose cohorts)
Number of subjects: 94
Study 29633515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent docetaxel (35 mg/m2 weekly or 75 mg/m2 every 3 weeks)
Number of subjects: 187
Study 29633515 — intervention group
Group type: COMPARATOR
Intervention: Continuous docetaxel (35 mg/m2 weekly or 75 mg/m2 every 3 weeks)
Number of subjects: 187
Study 29633515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent docetaxel
Number of subjects: 187
Study 29633515 — intervention group
Group type: COMPARATOR
Intervention: Continuous docetaxel
Number of subjects: 187
Study 27021377 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 Gy external beam radiation (EBR)
Number of subjects: 155
Study 27021377 — intervention group
Group type: COMPARATOR
Intervention: 0 Gy external beam radiation (EBR)
Number of subjects: 155
Study 25073921 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered saline solution
Number of subjects: 3014
Study 25073921 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 3014
Study 25073921 — intervention group
Group type: COMPARATOR
Intervention: Blood solution
Number of subjects: 3014
Study 22442773 — intervention group
Group type: EXPERIMENTAL
Intervention: Duralay II with Method 1
Number of subjects: 60
Study 22442773 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Pattern Resin with Method 1
Number of subjects: 60
Study 22442773 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Pattern Resin with Method 2
Number of subjects: 60
Study 22442773 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Pattern Resin with Method 3
Number of subjects: 60
Study 22442773 — intervention group
Group type: EXPERIMENTAL
Intervention: Duralay II with Method 2
Number of subjects: 60
Study 22442773 — intervention group
Group type: EXPERIMENTAL
Intervention: Duralay II with Method 3
Number of subjects: 60
Study 20606542 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve-sparing radical hysterectomy (NSRH)
Number of subjects: 31
Study 20606542 — intervention group
Group type: COMPARATOR
Intervention: Classical radical hysterectomy
Number of subjects: 31
Study 17511155 — intervention group
Group type: EXPERIMENTAL
Intervention: Compositae salviae dropping pill (CSDP)
Number of subjects: 81
Study 17511155 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (Control)
Number of subjects: 81
Study 15625210 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 63
Study 15625210 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 63
Study 11755280 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 13955
Study 11755280 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine
Number of subjects: 13955
Study 10357349 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ventilation (CV group, n = 15)
Number of subjects: 30
Study 10357349 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing (SB group, n = 15)
Number of subjects: 30
Study 7488576 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning laser ophthalmoscope (SLO) imaging at 590 nm, 670 nm, and 830 nm
Number of subjects: 19
Study 7488576 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning laser ophthalmoscope (SLO) imaging
Number of subjects: 19
Study 7488576 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal aperture in SLO imaging
Number of subjects: 19
Study 2021797 — intervention group
Group type: EXPERIMENTAL
Intervention: Short overall treatment time (less than or equal to 4 weeks) with 5 fractions per week regime
Number of subjects: 602
Study 2021797 — intervention group
Group type: EXPERIMENTAL
Intervention: Short overall treatment time (less than or equal to 4 weeks)
Number of subjects: 602
Study 2021797 — intervention group
Group type: COMPARATOR
Intervention: Long overall treatment time (greater than 4 weeks)
Number of subjects: 602
Study 7034788 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 77
Study 7034788 — intervention group
Group type: COMPARATOR
Intervention: Benson's Relaxation Response (BRR)
Number of subjects: 77
Study 7034788 — intervention group
Group type: COMPARATOR
Intervention: No Treatment (NT)
Number of subjects: 77
Study 31762338 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrox40
Number of subjects: 13
Study 31762338 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 13
Study 31329183 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation measures in the Department of Medical Rehabilitation
Number of subjects: 116
Study 31329183 — intervention group
Group type: COMPARATOR
Intervention: Control group in the Department of Neurology
Number of subjects: 116
Study 28616417 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training (role-playing and moulage training)
Number of subjects: 51
Study 28616417 — intervention group
Group type: COMPARATOR
Intervention: Oral training (lecture and short movie)
Number of subjects: 51
Study 28616417 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training
Number of subjects: 51
Study 25885095 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy Heart educational program (11-week group meetings of nutritional education)
Number of subjects: 37
Study 25885095 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient care (control group)
Number of subjects: 37
Study 25885095 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy Heart educational program
Number of subjects: 37
Study 25371147 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening heart failure (WHF)
Number of subjects: 1347
Study 22265386 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound+lidocaine
Number of subjects: 93
Study 22265386 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound+lidocaine
Number of subjects: 93
Study 22265386 — intervention group
Group type: COMPARATOR
Intervention: Control (sham ultrasound+lidocaine)
Number of subjects: 93
Study 20370860 — intervention group
Group type: EXPERIMENTAL
Intervention: Geri‐FITT
Number of subjects: 717
Study 20370860 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 717
Study 17369796 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon fiber eccentric chainring (EC)
Number of subjects: 11
Study 17369796 — intervention group
Group type: COMPARATOR
Intervention: Standard chainring (SC)
Number of subjects: 11
Study 16328746 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention for social anxiety disorder
Number of subjects: 35
Study 16328746 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 35
Study 11874410 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral hydrocortisone replacement (15 mg at 0800, 5 mg at 1700)
Number of subjects: 15
Study 11874410 — intervention group
Group type: COMPARATOR
Intervention: Physiological hydrocortisone infusion (PHI)
Number of subjects: 15
Study 10213464 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + natural IFN‐alpha (3 MU three times a week i.m.)
Number of subjects: 219
Study 10213464 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + recombinant IFN alpha‐2a (3 MU three times a week i.m.)
Number of subjects: 219
Study 10213464 — intervention group
Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 219
Study 7562888 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 4
Study 7562888 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg
Number of subjects: 4
Study 7562888 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 4
Study 7562888 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine-GITS 30 mg
Number of subjects: 4
Study 2161295 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 300 or 400 mg/m2 every 4 weeks
Number of subjects: 129
Study 7315769 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg fluoride as sodium fluoride in divided doses with meals
Number of subjects: 0
Study 7315769 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg fluoride as sodium fluoride in divided doses with meals
Number of subjects: 0
Study 7315769 — intervention group
Group type: COMPARATOR
Intervention: Control (no fluoride supplements)
Number of subjects: 0
Study 7315769 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg fluoride as sodium fluoride
Number of subjects: 0
Study 7315769 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg fluoride as sodium fluoride
Number of subjects: 0
Study 31407212 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 16
Study 31407212 — intervention group
Group type: COMPARATOR
Intervention: Neutral writing
Number of subjects: 16
Study 28771964 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU)
Number of subjects: 199
Study 28771964 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 199
Study 26481215 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m² and bevacizumab 15 mg/kg (Level 0 cohort)
Number of subjects: 21
Study 26481215 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 50 mg/m² and bevacizumab 15 mg/kg (Level 1 cohort)
Number of subjects: 21
Study 22873656 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin plus metronidazole (375 mg amoxicillin and 500 mg metronidazole, three times daily for 7 days)
Number of subjects: 82
Study 22873656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 17175037 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg)
Number of subjects: 22
Study 17175037 — intervention group
Group type: COMPARATOR
Intervention: Control (no orlistat)
Number of subjects: 22
Study 15309002 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial septal pacing
Number of subjects: 124
Study 15309002 — intervention group
Group type: COMPARATOR
Intervention: Right atrial appendage pacing
Number of subjects: 124
Study 11099993 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 150
Study 11099993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 9183841 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of music
Number of subjects: 0
Study 8473551 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) administration of clentiazem (20 mg)
Number of subjects: 24
Study 8473551 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral (PO) administration of clentiazem (80 mg)
Number of subjects: 24
Study 2869591 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (250 micrograms bolus followed by 300 micrograms/hr infusion)
Number of subjects: 4
Study 2869591 — intervention group
Group type: COMPARATOR
Intervention: Placebo (150 mm of NaCl)
Number of subjects: 4
Study 30509095 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ultrasound and CEUS
Number of subjects: 84
Study 30509095 — intervention group
Group type: EXPERIMENTAL
Intervention: p16 protein expression in para‐carcinoma tissues
Number of subjects: 84
Study 30509095 — intervention group
Group type: EXPERIMENTAL
Intervention: p16 positive and negative groups
Number of subjects: 84
Study 30509095 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of p16 expression with ultrasound parameters
Number of subjects: 84
Study 28595285 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with bevacizumab
Number of subjects: 326
Study 28595285 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without bevacizumab (Control)
Number of subjects: 326
Study 26552426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tree Theme Method (TTM)
Number of subjects: 0
Study 26552426 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 0
Study 23679147 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramaximal interval training (SMIT), n=20, 30 s at 130% AV, 150 s passive recovery, 7-12 bouts per session
Number of subjects: 75
Study 23679147 — intervention group
Group type: COMPARATOR
Intervention: Control group, n=16, 30 min continuous running at 75% AV
Number of subjects: 75
Study 23679147 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT), n=19, 4 min at 100% AV, 4 min passive recovery, 4-6 bouts per session
Number of subjects: 75
Study 21371242 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin once daily for 6 months
Number of subjects: 173
Study 21371242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 19645619 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths-based linkage intervention
Number of subjects: 316
Study 19645619 — intervention group
Group type: COMPARATOR
Intervention: Passive referral
Number of subjects: 316
Study 16882804 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 3350 without electrolytes
Number of subjects: 79
Study 16882804 — intervention group
Group type: COMPARATOR
Intervention: Milk of magnesia
Number of subjects: 79
Study 15542191 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant CMV gB vaccine
Number of subjects: 76
Study 15542191 — intervention group
Group type: EXPERIMENTAL
Intervention: gB canarypox vectored vaccine (ALVAC‐CMVgB)
Number of subjects: 76
Study 15542191 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified protein subunit with adjuvant
Number of subjects: 76
Study 15542191 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant canarypox
Number of subjects: 76
Study 11715153 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide pneumococcal vaccine
Number of subjects: 0
Study 9287241 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interferon-beta 1a (IFN-beta 1a)
Number of subjects: 793
Study 9287241 — intervention group
Group type: COMPARATOR
Intervention: CHO-derived IFN-beta 1a
Number of subjects: 793
Study 7902905 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 444
Study 7902905 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 444
Study 7902905 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors (age > 65 years, body weight < 70 kg, hypertension on admission)
Number of subjects: 444
Study 7902905 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 444
Study 3012807 — intervention group
Group type: EXPERIMENTAL
Intervention: Restriction endonuclease digestion of DNA from herpes simplex virus isolates
Number of subjects: 40
Study 3012807 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 of the 40 isolates)
Number of subjects: 40
Study 3012807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential isolates from a patient cleaved with Eco R1 and Hind III
Number of subjects: 40
Study 29694465 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (12 mg/day)
Number of subjects: 20
Study 29694465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26681487 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational booklet
Number of subjects: 85
Study 26681487 — intervention group
Group type: COMPARATOR
Intervention: No booklet (control)
Number of subjects: 85
Study 25516139 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU vitamin D3 monthly for two months then 100,000 IU monthly for a total of 18 months
Number of subjects: 322
Study 25516139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 22800449 — intervention group
Group type: EXPERIMENTAL
Intervention: +3.00 D aspheric AcrySof ReSTOR IOL
Number of subjects: 60
Study 22800449 — intervention group
Group type: COMPARATOR
Intervention: +4.00 D aspheric AcrySof ReSTOR IOL
Number of subjects: 60
Study 21092604 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracic surgery (VATS)
Number of subjects: 271
Study 18728266 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol, 200 mg twice daily for 4 weeks
Number of subjects: 30
Study 18728266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15749447 — intervention group
Group type: EXPERIMENTAL
Intervention: High tibial osteotomy (HTO), n=18
Number of subjects: 40
Study 15749447 — intervention group
Group type: COMPARATOR
Intervention: Unicompartmental knee arthroplasty (UKA), n=22
Number of subjects: 40
Study 14651755 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence Based Medicine (EBM) Knowledge Score; average score on the 12-point scale was 6.4; over 50% of respondents answered questions satisfactorily regarding critical appraisal methods and interpretation of results.
Number of subjects: 1000
Study 14651755 — intervention group
Group type: EXPERIMENTAL
Intervention: Importance of EBM principles to practice; 95% of respondents felt EBM principles were important.
Number of subjects: 1000
Study 10394342 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips SL‐25 linear accelerator (SL‐25‐MLC) with 6 MV photons and MLC
Number of subjects: 20
Study 10394342 — intervention group
Group type: COMPARATOR
Intervention: Philips SL‐75 linear accelerator (SL‐75) with 5 MV photons and tray‐mounted cerrobend blocks
Number of subjects: 20
Study 8961779 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental therapy
Number of subjects: 0
Study 8961779 — intervention group
Group type: COMPARATOR
Intervention: Alternative treatment or placebo
Number of subjects: 0
Study 1996745 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% at 37 degrees C
Number of subjects: 30
Study 1996745 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% at room temperature
Number of subjects: 30
Study 1996745 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% at 4 degrees C
Number of subjects: 30
Study 6435703 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin alone (group A)
Number of subjects: 17
Study 6435703 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin with tamoxifen (group B)
Number of subjects: 17
Study 31761834 — intervention group
Group type: EXPERIMENTAL
Intervention: BYM338 (bimagrumab) at doses of 10 mg/kg, 3 mg/kg, and 1 mg/kg administered intravenously every 4 weeks for 52 weeks
Number of subjects: 20
Study 31761834 — intervention group
Group type: EXPERIMENTAL
Intervention: BYM338 (bimagrumab)
Number of subjects: 20
Study 31761834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28386694 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1.09 g ethanol kg-1 fat-free body mass)
Number of subjects: 13
Study 28386694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 28386694 — intervention group
Group type: COMPARATOR
Intervention: Alcohol and Placebo (combined results)
Number of subjects: 13
Study 26773752 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) therapy
Number of subjects: 148
Study 26773752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 148
Study 26773752 — intervention group
Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 148
Study 24373114 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching group
Number of subjects: 56
Study 24373114 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 22455402 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-PACT web-based system
Number of subjects: 100
Study 18547778 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Behavior and Network Therapy
Number of subjects: 397
Study 18547778 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Number of subjects: 397
Study 18547778 — intervention group
Group type: EXPERIMENTAL
Intervention: General factors (not specific to treatment)
Number of subjects: 397
Study 17478412 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive patient website
Number of subjects: 37
Study 15023830 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (up to 12 treatments over three months)
Number of subjects: 401
Study 15023830 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 401
Study 11779264 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d or 120 mg/d)
Number of subjects: 7290
Study 11779264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7290
Study 9555668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron-saccharate and rhEPO treatment in group II patients
Number of subjects: 6
Study 9555668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron-saccharate and rhEPO treatment in group IV patients
Number of subjects: 6
Study 9555668 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (group I)
Number of subjects: 6
Study 9555668 — intervention group
Group type: COMPARATOR
Intervention: Absolute iron deficiency in group III patients
Number of subjects: 6
Study 8288664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (1.5 grams followed by 750 mg at 8 and 16 hours later for a total of one day)
Number of subjects: 1354
Study 8288664 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (1 gram every 8 hours for 9 doses for a total of three days)
Number of subjects: 1354
Study 2645933 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% plain
Number of subjects: 0